Loading
Life sciences · Journal article
Dyes and Pigments · October 3, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Phototheranostics, integrating real-time imaging with targeted therapy, represents a breakthrough in precision cancer treatment. However, conventional agents suffer from limited tissue penetration due to short-wavelength excitation/emission (<650 nm) and suboptimal efficacy from monomodal therapeutic mechanisms. To overcome these limitations, we engineered NCCy, a cationic donor-π-acceptor dye combining triphenylamine donors, coumarin-hemicyanine acceptors, and indole-derived cations. This design extends -conjugation to achieve red and near-infrared dual-channel fluorescence imaging capabilities, while leveraging the 60 mV mitochondrial membrane potential gradient for tumor-selective targeting. Under 660 nm irradiation, NCCy simultaneously generates singlet oxygen and hyperthermia, enabling synergistic photodynamic-photothermal therapy. In vitro studies demonstrated dual-channel fluorescence imaging-guided mitochondrial localization and reactive oxygen species/heat co-generation, inducing apoptosis. In 4T1 tumor-bearing mice, NCCy achieved rapid tumor accumulation (<1 h) with sustained retention, facilitating near-infrared image-guided therapy that suppressed 68% of tumor growth without systemic toxicity, as confirmed by histopathological analysis. This work establishes a molecular blueprint for deep-tissue-penetrating, multimodal phototheranostics, offering a clinically translatable strategy for precision oncology through spatiotemporally controlled treatment activation and microenvironment-responsive therapeutic synergy.